Development of a sensitive enzyme-linked immunosorbent assay for the measurement of biologically active etanercept in patients with ankylosing spondylitis

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1008, Issue , 2016, Pages 219-224

  Wang, Lei ^a   Wang, Xiaoxia ^a,b   Li, Ying ^a   Cheng, Zeneng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Ankylosing spondylitis; Biologically active; Enzyme linked immunosorbent assay; Etanercept; Pharmacokinetics

Indexed keywords

ANTIBODIES; DISEASES; ENZYMES; PATIENT MONITORING; PHARMACOKINETICS;

ANKYLOSING SPONDYLITIS; BIOLOGICALLY ACTIVE; CONCENTRATION DETECTIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; ETANERCEPT; RELATIVE STANDARD DEVIATIONS; THERAPEUTIC DRUG MONITORING; TUMOR NECROSIS FACTORS;

DRUG DOSAGE;

ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT;

ADULT; ANALYTIC METHOD; ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MALE; MEASUREMENT ACCURACY; PRIORITY JOURNAL; RELIABILITY; REPEATED DRUG DOSE; BLOOD; PROCEDURES; REPRODUCIBILITY; SPONDYLITIS, ANKYLOSING; VALIDATION STUDY;

ANTIRHEUMATIC AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETANERCEPT; HUMANS; REPRODUCIBILITY OF RESULTS; SPONDYLITIS, ANKYLOSING;

EID: 84949309736     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2015.12.001     Document Type: Article

References (21)

1. Dhillon S., Lyseng-Williamson K.A., Scott L.J. Etanercept. Drugs 2007, 67:1211-1241.
2. Malottki K., Barton P., Tsourapas A., Uthman A.O., Liu Z., Routh K., Connock M., Jobanputra P., Moore D., Fry-Smith A. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol. Assess. 2011, 15:1-6.
3. Feldmann M., Brennan F.M., Williams R.O., Elliott M.J., Maini R.N. Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action. J. Inflamm. 1994, 47:90-96.
4. Desplat-Jégo S., Burkly L., Putterman C. Targeting TNF and its family members in autoimmune/inflammatory disease. Mediat. Inflamm. 2014, 2014:1-2.
5. Smolen J.S., Landewé R., Breedveld F.C., Buch M., Burmester G., Dougados M., Emery P., Gaujoux-Viala C., Gossec L., Nam J. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 2013, 0:1-18.
6. Neovius M., Arkema E.V., Olsson H., Eriksson J.K., Kristensen L.E., Simard J.F., Askling J., Bäcklund E., Cöster L., Forsblad-d'Elia H. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann. Rheum. Dis. 2015, 74:354-360.
7. Ferrara N., Gerber H., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
8. Rogers L.M., Veeramani S., Weiner G.J. Complement in monoclonal antibody therapy of cancer. Immunol. Res. 2014, 59:203-210.
9. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., Braun D., Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 2012, 366:1190-1199.
10. Ternant D., Ceze N., Lecomte T., Degenne D., Duveau A.C., Watier H., Dorval E., Paintaud G. An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. Ther. Drug Monit. 2010, 32:647-652.
11. Don B.R., Spin G., Rose A., Nestorov I., Hutmacher M., Kaysen G.A. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J. Pharm. Pharmacol. 2005, 57:1407-1413.
12. Kawai S., Sekino H., Yamashita N., Tsuchiwata S., Liu H., Korth-Bradley J.M. The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. J. Clin. Pharmacol. 2006, 46:418-423.
13. Lon H., Liu D., Zhang Q., DuBois D.C., Almon R.R., Jusko W.J. Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis. Pharm. Res. 2011, 28:1622-1630.
14. Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J. Clin. Pharmacol. 2005, 45:490-497.
15. Madaboosi N., Soares R.R., Chu V., Conde J.P. A microfluidic immunoassay platform for the detection of free prostate specific antigen: a systematic and quantitative approach. Analyst. 2015, 140:4423-4433.
16. Crowther J.R. ELISA. Theory and practice. Methods Mol. Biol. 1995, 42:1-218.
17. Crowther J.R. The ELISA guidebook. Methods Mol. Biol. 2000, 149:1-413.
18. DeSilva B., Smith W., Weiner R., Kelley M., Smolec J., Lee B., Khan M., Tacey R., Hill H., Celniker A. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 2003, 20:1885-1900.
19. Lee J.W., Kelley M., King L.E., Yang J., Salimi-Moosavi H., Tang M.T., Lu J., Kamerud J., Ahene A., Myler H. Bioanalytical approaches to quantify total and free therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 2011, 13:99-110.
20. Fang Y., Li L., Wang R., Huang F., Song H., Tang Z., Li Y., Guan H., Zheng Q. Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. Acta Pharmacol. Sin. 2010, 31:1500-1507.
21. Elewski B., Leonardi C., Gottlieb A.B., Strober B.E., Simiens M.A., Dunn M., Jahreis A. Comparison of clinical and pharmacokinetic profiles of etanercept 25mg twice weekly and 50mg once weekly in patients with psoriasis. Br. J. Dermatol. 2007, 156:138-142.